Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic Plaques

Maulik D. Majmudar, Jeongsoo Yoo, EDMUND J. KELHER, Jessica J. Truelove, Yoshiko Iwamoto, Brena Sena, Partha Dutta, Anna Borodovsky, Kevin Fitzgerald, Marcelo F. Di Carli, Peter Libby, Daniel G. Anderson, Filip K. Swirski, Ralph Weissleder, Matthias Nahrendorf

Rationale: Myeloid cell content in atherosclerotic plaques associates with rupture and thrombosis. Thus, imaging of lesional monocytes and macrophages could serve as a biomarker of disease progression and therapeutic intervention.

Objective: To noninvasively assess plaque inflammation with dextran nanoparticle (DNP)-facilitated hybrid positron emission tomography/magnetic resonance imaging (PET/MRI).

Methods and Results: Using clinically approved building blocks, we systematically developed 13-nm polymeric nanoparticles consisting of cross-linked short chain dextrans, which were modified with desferoxamine for zirconium-89 radiolabeling (89Zr-DNP) and a near-infrared fluorochrome (VT680) for microscopic and cellular validation. Flow cytometry of cells isolated from excised aortas showed DNP uptake predominantly in monocytes and macrophages (76.7%) and lower signal originating from other leukocytes, such as neutrophils and lymphocytes (11.8% and 0.7%, P < 0.05 versus monocytes and macrophages). DNP colocalized with the myeloid cell marker CD11b on immunohistochemistry. PET/MRI revealed high uptake of 89Zr-DNP in the aortic root of apolipoprotein E knock out (ApoE−/−) mice (standard uptake value, ApoE−/− mice versus wild-type controls, 1.9±0.28 versus 1.3±0.03; P < 0.05), corroborated by ex vivo scintillation counting and autoradiography. Therapeutic silencing of the monocyte-recruiting receptor C-C chemokine receptor type 2 with short-interfering RNA decreased 89Zr-DNP plaque signal (P < 0.05) and inflammatory gene expression (P < 0.05).


Key Words: atherosclerosis ■ inflammation ■ macrophage ■ molecular imaging ■ nanoparticles ■ PET/MRI

During atherogenesis, monocytes and macrophages (Mo/Mφ) invade the arterial intima and sustain and amplify local inflammation through secretion of cytokines, reactive oxygen species, and proteolytic enzymes. These innate immune cells may differentiate into foam cells and favor degradation of extracellular matrix macromolecules and thinning of the fibrous cap, features of plaques that have ruptured and triggered myocardial infarction or stroke. Macrophage-targeted imaging may provide the opportunity to detect upstream events that play a causative role in disease progression and thus enable preventive therapy. Iron oxide nanoparticle uptake assessed by magnetic resonance imaging (MRI) has begun to address this need, but this approach is mostly semiquantitative, and the detection sensitivity for these nanoparticles is about 50 times lower compared with radioisotope imaging.

In This Issue, see p 743

This study aimed to develop a sensitive, clinically viable technique for detection of inflammatory leukocytes in atherosclerotic plaque with positron emission tomography (PET). The approach used core-free dextran nanoparticles (DNP) made from clinically approved components, labeled with desferoxamine to chelate the PET isotope zirconium-89 (89Zr). Dextran is biocompatible and biodegradable, making it a suitable starting material for nanoparticles intended for clinical use. We tested DNPs using hybrid PET/MRI...
for detecting macrophages in atherosclerotic plaques in apolipoprotein E knock out (ApoE−/−) mice. MRI provided the anatomic reference for the source of the PET signal, which reported on nanoparticle deposition in the vessel wall. We further used the PET macrophage reporter 89Zr-DNP to assess the efficacy of a therapeutic intervention, Mo/Mφ-targeted RNA interference. Using lipidoid nanoparticle-enabled silencing of C-C chemokine receptor type 2 (CCR2), we followed plaque inflammation with 89Zr to give 89Zr-DNP. The radiochemical yield and purity of the nanoparticle was achieved at room temperature by complexing remaining amines were succinylated. The quantitative radiolabeling was then further amplified using the QuantiTect Whole Transcriptome RNeasy Micro Kit (Qiagen) using manufacturer’s protocol. One microgram of mRNA was used to generate complimentary DNA (cDNA) using a high capacity RNA to cDNA kit (Applied Biosystems). CDNA was then further amplified using the Quantitect Whole Transcriptome

<table>
<thead>
<tr>
<th>Nonstandard Abbreviations and Acronyms</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCR2</td>
</tr>
<tr>
<td>DNP</td>
</tr>
<tr>
<td>FDG</td>
</tr>
<tr>
<td>Mo/Mφ</td>
</tr>
<tr>
<td>PET</td>
</tr>
</tbody>
</table>

**Methods**

**DNP Synthesis**

Dextran (10 kDa; Amersham Biosciences, Sweden) was cross-linked with epichlorohydrin followed by partial amination with ethylene diamine to yield amino-DNPs. DNP-NH2 was modified with p-isothiocyanatobenzyl-desferoxamine (SCN-Bz-Df; Macrocyclics, TX) and the N-hydroxyssuccinimidyl ester of the near-infrared fluorochrome VivoTag680 (VT680; PerkinElmer, Waltham, MA). The remaining amines were succinylated. The quantitative radiolabeling of the nanoparticle was achieved at room temperature by complexation with 89Zr to give 89Zr-DNP. The radiochemical yield and purity of 89Zr-DNP were determined using radio-thin-layer chromatography using and instant thin-layer chromatography plates and 50 mmol/L EDTA as a mobile phase.

**siRNA Nanoparticle Synthesis**

siRNA (short-interfering RNA) synthesis and formulation into lipid nanoparticles used previously described methods. The RNA duplex for silencing CCR2 was 5′-uGcuAaAXcuGcuGcAAAdTsdT-F3′ (sense), 5′-UUUG eAGACGcGUuAcGAdTsdT-3′ (antisense), a sequence known to limit CCR2 expression. Single-strand RNAs were produced, annealed, and used as duplexes. The nanocarrier for siRNA delivery was prepared with a cationic lipid using a spontaneous vesicle formation procedure. Lipids were dissolved in 90% ethanol and mixed with siRNA solution (1:1 ratio) at fixed speed and diluted immediately with PBS to final 25% ethanol concentration. The ethanol was then removed and the external buffer was replaced with PBS by dialysis.

**Animal Experiments**

Female C57Bl/6 (n=10) and ApoE−/− mice (n=22) were purchased from the Jackson Laboratory (Jackson, MI). C57Bl/6 (B6) mice were 12 to 16 weeks of age. ApoE−/− mice had an average age of 28 weeks and consumed a high-cholesterol diet (Harlan Teklad, 0.2% total cholesterol) for at least 16 weeks, conditions that reliably produce atherosclerotic plaques in the aortic root and arch. Mice were anesthetized for all procedures (isoflurane 1.5%; O2 2 L/min). Animal experiments were approved by Massachusetts General Hospital’s Institutional Subcommittee on Research Animal Care.

**Treatment Protocols**

To test 89Zr-DNP as a biomarker of therapeutic efficiency, we treated a cohort of ApoE−/− mice with tail vein injections of siRNA targeting CCR2 (siCCR2, n=5) or siRNA targeting luciferase as control (siCON, n=5) at a dose of 0.5 mg/kg. Mice were age-matched and allocated randomly to groups (siCON versus siCCR2).

**Flow Cytometry**

ApoE−/− mice were euthanized 24 hours after injection of DNP (5 nmol VT680) for flow cytometry analysis (n=3–4 per group). Aortas were excised under a dissecting microscope and minced in medium containing 450 U/mL collagenase I, 125 U/mL collagenase XI, 50 U/mL DNase I, and 60 U/mL hyalurondase (Sigma-Aldrich), and incubated at 37°C for 1 hour with agitation at 750 rpm. Aortas were processed in PBS with 0.5% bovine serum albumin and 1% fetal bovine serum (FACS buffer). The processed single-cell suspensions (300 μL) were stained with fluorochrome-labeled antibodies (BD Biosciences) against mouse leukocyte markers as follows: a phycoerythrin anti-mouse lineage antibody cocktail containing antibodies directed against CD90, B220, CD49b, NK1.1, Ly-6G, and Ter-119 was used. Myeloid cells were then stained with antimouse CD11b, F4/80, and Ly-6C. Monocytes were defined as (CD90/B220/CD49b/NK1.1/Ly-6G/Ter-119)low, CD11bhigh, F4/80high, Ly-6Cint. Macrophages were defined as (CD90/B220/CD49b/NK1.1/Ly-6G/Ter-119)low, CD11bhigh, F4/80high, Ly-6Cint. Neutrophils were defined as (CD90/B220/CD49b/NK1.1/Ly-6G/Ter-119)high and CD11bhigh. Lymphocytes were defined as (CD90/B220/CD49b/NK1.1/Ly-6G/Ter-119)high and CD11bhigh. Flow cytometry was performed on a multicolor flow cytometer (LSR II, BD Biosciences).

**Histological Examination**

Histological examination of aortic roots was performed 24 hours after injection of DNP-VT680. Aortas were excised, rinsed in PBS, embedded in optimal cutting temperature compound (Sakura Finetek) and flash-frozen in a 2-methylbutane bath with dry ice. Fresh-frozen 6 to 10 μm thick serial sections were prepared and immunohistochemically stained for the myeloid cell marker CD11b (clone: M1/70, BD Biosciences). On adjacent sections, immunofluorescence staining was performed to analyze microscopic DNP distribution and colocalization with CD11b positive cells. The sections were stained with FITC-CD11b (clone: M1/70, BD Biosciences), and the slides were coverslipped using a mounting medium with DAPI (Vector Laboratories Inc.). Fluorescence microscopy was performed using a Nikon BX63 equipped with a Cascade Model 512B camera (Roper Scientific), a Cy5.5 filter cube (HQ650/45x EX, dichroic 670LBP BS, and HQ710/50 m EM), a fluorescein isothiocyanate filter cube (HQ480/40x EX, dichroic Q505LBP BS, HQ535/50 m EM), and a UV filter cube (D365/10x EX, dichroic 365LBP BS, E400LPv2 EM) (Chroma Technology Corp). Capturing of images of stained sections used a digital slide scanner, NanoZoomer 2.0RS (Hamamatsu, Japan).

**Biodistribution and Autoradiography**

The blood half-life of 89Zr-DNP was determined with serial retroorbital bleeds after injection of 150 Ci of 89Zr-DNP into the tail vein of 5 B6 mice. After killing (48 hours), mice were perfused with 10 mL of PBS. Organs were harvested, weighed, and their activity was recorded with a γ counter (1480 Wizard 3-inch PerkinElmer, Waltham, MA). Biodistribution data were corrected for radioactive decay and residual radioactivity at the injection site. Oil-Red-O staining depicted the distribution of plaques in ApoE−/− aortas that were subsequently photographed by a digital camera as well as analyzed by digital autoradiography. Aortas were exposed to a phosphorimager plate and read with a Typhoon FLA9000 system (GE Healthcare) 4 hours later. Visualization of scanned autoradiography images was performed using the ImageJ program (Image J 1.44o, National Institute of Health, Bethesda, MD).

**Quantitative Reverse-Transcriptase Polymerase Chain Reaction**

Messenger RNA was extracted from the aortic root and arch using a RNeasy Micro Kit (Qiagen) using manufacturer’s protocol. One microgram of mRNA was used to generate complimentary DNA (cDNA) using a high capacity RNA to cDNA kit (Applied Biosystems). CDNA was then further amplified using the QuantiTect Whole Transcriptome...
kit (Qiagen). The amplified cDNA was diluted at a ratio of 1:10 in DNase- and RNase-free H$_2$O and 2 µL of final cDNA was used for further analysis. Levels of mRNAs encoding target genes used Taqman assays (Applied Biosystems). Variability in cDNA concentration was normalized using GAPDH, a constitutively expressed gene.

PET-CT Imaging
Imaging experiments were performed 48 hours after injection of $^{89}$Zr-DNP at 354±13 µCi/mouse. All PET-computed tomography (CT) images were acquired on a Siemens Inveon micro PET-CT. Each PET acquisition was ≈90 minutes in duration. PET was reconstructed from 600 million coincidental 511 keV photon counts. Counts were rebinned in 3-dimension by registering photons spanning ≤3 consecutive rings, then reconstructed into sinograms by using a high-resolution Fourier Rebin algorithm. Image pixel size was anisotropic, with dimensions of 0.796 mm in the z direction and 0.861 mm in the x and y directions, for a total of 512x512x768 pixels. Data are expressed as standard uptake values, which normalize radioactivity for body weight and injected dose. Blood signal was used to calculate the target:background ratio.

CT images were reconstructed from 360 projections of X-rays with a cone beam angle of 9.3° over 360° perpendicular to the animal bed. Eighty kiloelectronVolts X-rays were transmitted from a 500 µA anode source, 347 mm from the center of rotation and recorded on a CCD detector, containing 2048 transaxial and 3072 axial pixels. Isotropic CT pixel size was 110.6 µm, with a total of 512x512x768 pixels. Projections were acquired at end expiration using a BioVet gating system (M2M Imaging, Cleveland, OH), and CT acquisition time was ≈10 minutes. Reconstruction of data sets used IRW software (Siemens).

PET/MR Registration and Fusion
In vivo MRI was performed for anatomic reference immediately after PET/CT imaging in ApoE−/− mice with or without siCCR2 treatment. Cine images were obtained on a 7-Tesla Bruker Phasenscan with ECG and respiratory gating (SA Instruments, Inc, Stony Brook, NY) using a fast gradient echo FLASH sequence with the following parameters: echo time 2.7 ms; 16 frames per R-R interval (repetition time 7.0-15.0 ms); resolution 200 µm × 200 µm × 1 mm; number of excitations 4; flip angle 60°. PET/CT and MR images were acquired sequentially using a custom-designed mouse bed and a PET-CT gantry adapter. Offline fusion was based on external fiducial markers. A custom-built mouse vest of several loops of PE50 tubing was filled with 1% amine and 1 fluorochrome moieties were attached per particle. The radiolabeling yield of $^{89}$Zr-DNP (Figure 1A and 1B) was ≈99.5%. After centrifugation, the radiochemical purity was >99.5%. $^{89}$Zr-DNP was injected into 5 B6 mice to measure the nanoparticle’s kinetics in vivo. $^{89}$Zr-DNP had a blood half-life of 3.73±0.33 hours (R² of fit = 0.95; Figure 1C). Biodistribution of $^{89}$Zr-DNP at 48 hours was as follows (expressed as %ID/g): liver, 11.1±1.4; spleen, 10.3±1.8; lymph node, 5.3±0.9; blood, 4.7±1.0; kidney, 3.4±0.2; heart, 1.2±0.2; aorta, 1.2±0.1; tail, 0.9±0.2; lung, 1.0±0.4; intestines, 0.9±0.1; fat, 0.6±0.1; and muscle, 0.4±0.1 (Figure 1D).

Statistics
Results are expressed as mean±SEM. Differences between groups were evaluated by Student’s test. We used GraphPad Prism 4.0c for statistical analysis. A probability value of <0.05 was used to indicate statistical significance.

Results
Nanoparticle Preparation, Blood Half-life, and Biodistribution
The core-free nanoparticles used in this study consisted of polymeric dextran and had a mean particle size of 13.3 nm as determined by laser light scattering. On average, 8 desferoxamine and 1 fluorochrome moieties were attached per particle. The radiolabeling yield of $^{89}$Zr-DNP (Figure 1A and 1B) was >99.5%. After centrifugation, the radiochemical purity was 100%. $^{89}$Zr-DNP was injected into 5 B6 mice to measure the nanoparticle’s kinetics in vivo. $^{89}$Zr-DNP had a blood half-life of 3.73±0.33 hours (R² of fit = 0.95; Figure 1C). Biodistribution of $^{89}$Zr-DNP uptake in atherosclerotic aortic root plaques was quantified with PET, whereas MRI provided the anatomic reference. The aortic root and arch of ApoE−/− mice had significantly higher activity compared with wild-type controls (standard uptake value 1.85±0.28 versus 1.25±0.03 and 1.46±0.09 versus 0.98±0.04; P<0.05 for both; Figure 2A and 2B). The target-to-background ratio in aortic root and arch of ApoE−/− mice also significantly exceeded that in wild-type controls (aortic root and arch, 2.56±0.19 versus 1.64±0.03, and 2.16±0.34 versus 1.29±0.07; P<0.05 for both).

Ex Vivo Scintillation Counting and Autoradiography Confirm In Vivo PET/MRI
After imaging, we measured radioactivity in excised aortas by scintillation counting and autoradiography exposure. Compared with wild type, the percent injected dose per gram tissue (%ID/g) was significantly higher activity compared with wild-type controls (standard uptake value 1.85±0.28 versus 1.25±0.03 and 1.46±0.09 versus 0.98±0.04; P<0.05 for both; Figure 2A and 2B). The target-to-background ratio in aortic root and arch of ApoE−/− mice also significantly exceeded that in wild-type controls (aortic root and arch, 2.56±0.19 versus 1.64±0.03, and 2.16±0.34 versus 1.29±0.07; P<0.05 for both).
Nanoparticle uptake in atherosclerotic plaques in the aortic root was assessed using fluorescence microscopy (Figure 3). Microscopic images of adjacent sections stained for the mononuclear phagocyte antigen CD11b showed colocalization of myeloid cells with DNP in aortic root plaques (Figure 3A and 3B). CD11b is expressed primarily by monocytes, macrophages, and neutrophils. Imaging of sections in the lower-wavelength fluorescein isothiocyanate channel confirmed the specificity of the observed signal for nanoparticles rather than autofluorescence (Figure 3C). Higher magnification immunofluorescent microscopy after immunoreactive staining with CD11b corroborated colocalization of the DNP signal to CD11b+ cells (Figure 3D–3F).

**DNP Accumulate in Plaque Leukocytes**

Nanoparticle uptake in atherosclerotic plaques in the aortic root was assessed using fluorescence microscopy (Figure 3). Microscopic images of adjacent sections stained for the mononuclear phagocyte antigen CD11b showed colocalization of myeloid cells with DNP in aortic root plaques (Figure 3A and 3B). CD11b is expressed primarily by monocytes, macrophages, and neutrophils. Imaging of sections in the lower-wavelength fluorescein isothiocyanate channel confirmed the specificity of the observed signal for nanoparticles rather than autofluorescence (Figure 3C). Higher magnification immunofluorescent microscopy after immunoreactive staining with CD11b corroborated colocalization of the DNP signal to CD11b+ cells (Figure 3D–3F).

**Cellular Sources of the Nanoparticle Signal**

Quantification of DNP uptake into specific leukocyte populations (monocytes, macrophages, neutrophils, and lymphocytes) used multicolor flow cytometry detection of cell surface markers and the fluorochrome-labeled nanoparticle taken up by respective cells. Aortas were excised and cells isolated 24 hours after injection of DNP. Single-cell suspensions were stained with an antibody cocktail for specific leukocyte cell surface markers, and the fluorescence signal of DNP was compared for different cells. Flow cytometry revealed that the majority of DNP accumulated in Mo/Mφ (Figure 4); however, 23% of the cellular signal derived from other sources. This observation suggests that although the majority of the PET signal in atherosclerotic plaques resulted from uptake of nanoparticles by Mo/Mφ, DNP was not entirely specific for those cells but also taken up to some degree by neutrophils and lymphocytes. Of note, flow cytometry does not detect extracellular signal.

**PET/MRI Detects Therapeutic Effects of In Vivo RNAi**

Further experiments assessed the use of 89Zr-DNP PET/MRI for following the efficacy of a therapeutic intervention; silencing of CCR2, the monocytic chemokine receptor responsible for migration of the inflammatory monocyte subset to sites of inflammation using siRNA technology. siRNA silencing of CCR2 (siCCR2) significantly attenuates receptor protein expression in circulating and splenic monocytes.6 This intervention lowered the PET/MRI 89Zr-DNP signal in association with attenuated monocyte recruitment. The aortic roots of siCCR2-treated ApoE−/− mice had decreased PET signal when compared with ApoE−/− mice treated with an irrelevant siRNA. The target-to-background ratio changed from 2.25±0.11 to 1.82±0.10; P<0.03 (Figures 5A and 5B).
After imaging, quantitative reverse-transcriptase polymerase chain reaction of aortic extracts assessed gene expression. Systemic silencing of CCR2 reduced the expression of genes involved in vascular inflammation. Expression of CCR2, vascular cell adhesion molecule-1, interleukin-6, and tumor necrosis factor-α fell in siCCR2-treated mice, whereas transforming growth factor-β and arginase 1 gene expression rose (Figure 5C).

**Discussion**

Timely identification of patients with high risk for myocardial infarction or stroke remains challenging. It is even more difficult to predict the risk of rupture for a specific atherosclerotic plaque, a thrombotic trigger tightly linked to inflammation. Identification of inflamed atheromata could trigger aggressive risk factor modification, intensive pharmacological treatment,
and perhaps other preemptive interventions to enhance lesion stability and reduce the probability of plaque rupture and thrombosis. Thus, techniques for assessment of plaque inflammation might aid prevention of myocardial infarction and stroke. Inflammatory Mo/Mϕ play a central role in the pathobiology of plaque complication. Because these cells elaborate matrix-degrading proteases implicated in plaque rupture, they furnish attractive imaging biomarkers for plaque instability. The current work focused on the detection of inflammatory myeloid cells in atheromata with clinically viable, radioisotope-labeled DPNs without a metal core. Hybrid PET/MRI detection of these nanoparticles permitted tracking of RNAi-mediated silencing of CCR2, a chemokine receptor that mediates the recruitment of inflammatory monocytes in the arterial intima.

Previous studies have used PET for macrophage imaging, especially with fluorodeoxyglucose (18F-FDG). PET has interest for detection of cellular and molecular targets because it is the most sensitive noninvasive clinical imaging technology and permits quantitation. 18F-FDG has widespread clinical availability, and studies have correlated 18F-FDG uptake to the macrophage content of atheromata. Yet, 18F-FDG uptake lacks specificity for macrophages. Many other cells, including cardiomyocytes, smooth muscle cells, and other leukocytes, all of which are present in or close to atherosclerotic plaques, accumulate high amounts of glucose, making specific imaging of plaque inflammation with 18F-FDG challenging in the coronary arteries. A recent study showed that hypoxia, but not pro-inflammatory cytokines, augments glucose uptake by human macrophages. Thus, there is an unmet need for more specific macrophage-targeted imaging agents. In contrast to 18F-FDG, DNP report on phagocytic rather than metabolic activity. In the current work, 13-nm DPNs were designed for clinical translatability. These nanoparticles are composed of clinically approved materials, including small cross-linked dextran strands, and do not contain a metal core; hence, they are not detectable with MRI. Modified with desferoxamine, a clinically approved metal chelator, the nanoparticles were labeled with zirconium-89 for PET imaging. Zirconium-89 has a slow radioactive decay matching the in vivo kinetics of the 13-nm DNP. Therefore, imaging can be done after the nanoparticles have cleared from the blood pool yielding a low-background signal. DNP could also be labeled with other PET isotopes. If a smaller particle size accelerated pharmacokinetics, shorter injection-imaging sequences may facilitate fluorine-18 labeling. Importantly, 89Zr-DNP are easily biodegradable, supporting translation to humans.

Although PET and MRI were done sequentially and data were fused offline in our study, newer scanners allow for synchronous data acquisition in mice and in patients. Our data highlight the advantages of combining both modalities. MRI is a leading modality for imaging the cardiovascular system, and may thus prove to be particularly useful in conjunction with PET. Sparse molecular or cellular targets can be quantitated by PET, whereas MRI delivers high-contrast, high-resolution, and time-resolved cardiovascular imaging without additional radiation exposure. This approach permits analysis of molecular targets in anatomic and physiological context because MRI may deliver information on tissue motion and strain, blood flow, oxygenation, diffusion, and fiber orientation. PET/MRI could also enable dual target molecular imaging by simultaneous use of MRI agents. For example, one could use 89Zr-DNP for imaging of inflammation in conjunction with MR agents that detect cell death, collagen, or fibrin deposition.

Preclinical and clinical studies have highlighted the role of chronic persistent inflammation in the pathophysiology of atherosclerosis; hence specific anti-inflammatory therapy might produce clinical benefit. Here, we encapsulated siRNA in lipidoid nanoparticles for delivery to phagocytic cells. The target was CCR2, a receptor for the chemokine monocyte chemotactic protein-1 that specifically recruits the inflammatory monocyte subset to sites of inflammation in mice and in humans. As shown in landmark studies on the role of this chemokine/chemokine receptor axis, deficiency of either CCR2 or monocyte chemotactic protein-1 prevents recruitment of monocytes, thereby reducing macrophage burden and inflammation in plaques. We previously validated the delivery of siRNA to circulating and splenic monocytes by lipidoid nanoparticles and the efficiency of CCR2 silencing for the RNA target sequence. The splenic monocyte reservoir is particularly a suitable target because these cells rapidly ingest lipidoid nanoparticles used for siRNA delivery. In atherosclerotic mice, the spleen contributes monocytes to atherosclerotic plaque. Our current study followed monocyte-targeted siRNA therapy by plaque macrophage PET/MRI. We found significantly reduced PET signal in the aortic root and arch of ApoE−/− mice treated with siCCR2. The decreased macrophage PET signal was accompanied by a significantly reduced inflammatory gene expression pattern in the imaged arterial bed. The expression of CCR2 and several other proinflammatory genes fell, whereas the mRNAs that encode transforming growth factor-β and arginase 1, genes associated with resolution of inflammation, increased. Future studies will clarify whether 89Zr-DNP PET/MRI will be useful for imaging of therapeutic efficiency.

In conclusion, this study demonstrates the feasibility of nanoparticle-facilitated hybrid PET/MRI of inflammatory leukocytes in murine atherosclerotic plaques. The majority of cellular 89Zr-DNP signal (77% by flow cytometry) was derived from Mo/Mϕ; hence, the cellular specificity was limited. Specific targeting of monocyte recruitment with RNAi reduced the macrophage PET signal and dampened inflammation in plaques. Clinical translation of this cellular imaging strategy could identify macrophage-rich plaques at risk for complications and evaluate the effectiveness of macrophage-targeted therapies in atheromata.

Acknowledgments
We gratefully acknowledge Matt Sebas (Center for Systems Biology imaging core, MGH), the medium scale synthesis group for preparing the C-C chemokine receptor type 2 siRNA; Will Cantley for making the liposomal formulation; and Victor Koteliantsy, Tatiana Novobrantseva for helpful discussions (Alnylam). Sources of Funding
This project has been funded in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (HHSN268201000044C, R01-HL096576, R01-HL095629, and T32-HL094301).
Disclosures

Anna Borodovsky and Kevin Fitzgerald are full-time employees at Alnylam. Daniel Anderson holds Alnylam shares.

References


Novelty and Significance

What Is Known?

• Macrophages are effector cells of innate immunity that can destabilize atherosclerotic plaques by secreting proinflammatory cytokines and proteases.
• Macrophages have been linked to plaque rupture, which leads to myocardial infarction and stroke in patients with atherosclerosis.
• Nanoparticles are avidly taken up by macrophages and may report on plaque stability.

What New Information Does This Article Contribute?

• Nanoparticles made from dextran building blocks accumulate in macrophages that reside in atherosclerotic plaques.
• Derivatization of these particles with the radioactive isotope zirconium-89 enables imaging of aortic plaques of apoe-/- mice by positron emission tomography.
• In vivo silencing of monocyte C-C chemokine receptor type 2 receptor reduces the nanoparticle imaging signal and attenuates inflammatory gene expression.

Many ischemic complications arise from atherosclerotic plaques that do not significantly obstruct blood flow. Conventional anatomic imaging therefore cannot predict which lesions are at high risk of rupture. However, this information could guide individual risk assessment and direct preventive therapy. In this study, we describe the use of 13-nm dextran nanoparticles for imaging plaque inflammation in mice with atherosclerosis. Nanoparticles were derivatized with a radioactive isotope and detected by positron emission tomography, joined with magnetic resonance imaging for anatomic reference. Mice with silenced monocyte chemokine receptor C-C chemokine receptor type 2 accumulated fewer inflammatory cells in atherosclerotic lesions, in parallel with reduced expression of inflammatory genes. Clinical translation of this technology may be helpful in identifying patients at risk for plaque rupture and for developing preventive measures to avoid the outcomes of thrombotic events, such as stroke and acute myocardial infarction.
Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic Plaques

Maulik D. Majmudar, Jeongsoo Yoo, Edmund J. Keliher, Jessica J. Truelove, Yoshiko Iwamoto, Brena Sena, Partha Dutta, Anna Borodovsky, Kevin Fitzgerald, Marcelo F. Di Carli, Peter Libby, Daniel G. Anderson, Filip K. Swirski, Ralph Weissleder and Matthias Nahrendorf

_Circ Res._ 2013;112:755-761; originally published online January 8, 2013; doi: 10.1161/CIRCRESAHA.111.300576

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/112/5/755

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org//subscriptions/